Marlborough

A new drug from Sunovion Pharmaceuticals aimed at reducing seizures associated with epilepsy is now available by prescription in pharmacies across the United States.

Losses mounted and revenue declined in 2013 for Advanced Cell Technology (ACT) of Marlborough, which announced its financial results for fiscal 2013 Tuesday.

A Marlborough telecommunications company says its name is being maligned following an action by the government of the African nation of Rwanda. In a statement, TelexFREE said that, according to a published report in Rwanda Eye, a news medium in that country, a company with a similar name, P.L.I. TelexFree (Rwanda) Ltd., failed to pay taxes in that country of more than $6 million, has been channeling millions of dollars through Rwandan accounts, and is suspected of crimes ranging from tax evasion to money laundering. Subsequently, Rwanda Eye reported, the government banned all operations of P.L.I. TelexFree Rwanda.

A Boston-based real estate investment firm has purchased a large, vacant office building for $5.26 million.

The former treasurer of a nonprofit organization in Marlborough accused of misappropriating charity money for personal use has been ordered to pay $50,000 in restitution.

Marlborough-based Advanced Cell Technology said a new stem cell development method might allow for treatment for additional types of inflammatory and autoimmune conditions.

The MetroWest solar industry has a new competitor in Vivint Solar, a Utah-based company that already has the lion's share of the residential solar market in Massachusetts. A subsidiary of Vivint Inc., Vivint Solar opened its new office at 53 Brigham St. in Marlborough earlier this month.

A Marlborough-based manufacturer of solid-state silicon motion sensors has raised $8 million in capital to execute its development of sensor products for high-end markets.

A Marlborough biotech company is reporting positive results from the second phase of a test for a drug intended to treat Type 2 diabetes. Theracos Inc. said the 96-week study, which involved 288 subjects with the disease from the U.S., Mexico and Colombia evaluated the effectiveness of its THR1442 drug, which is a sodium-glucose co-transporter 2, or SGLT2.

Marlborough-based Advanced Cell Technology announced Monday that it will restate financial results between 2009 and 2013 because it misapplied accounting guidance related to stock warrants issued in September 2005.